NPI registry status
Active
2026 NPPES data Medical Oncology Physician NPI 1396726113 MD PHD
Verify on CMS → Michael Hurwitz, MD PHD
Medical Oncology Physician in New Haven, Connecticut.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 4,028 in Medical Oncology Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
1K
Medicare Part D claims · 163 beneficiaries · Medical Oncology Physician avg: 732
Generic prescribing
70%
generic claims · 30% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
73.6/100
▼ 10 pts below national avg 83.5 · Mid-tier
Source: CMS Medicare Part D Prescriber Public Use File, 2024
What the federal data shows
Michael Hurwitz, MD PHD reported a CMS MIPS final score of 73.6/100 - below the 83.5 national average - and filed 1,441 Medicare Part D claims in 2024.
- 73.6/100
- MIPS score · -10 vs avg
- 1K
- Part D claims, 2024
- 70%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Federal trust snapshot
What official records show about Michael Hurwitz, MD PHD
Federal records show an active NPI with both Medicare prescribing volume and a measured CMS quality score — objective registry data, not patient reviews.
- Verified
NPI registry status
Active listing in the CMS National Provider Identifier Registry (NPI 1396726113), first enumerated 11/09/2005.
Source: CMS NPPES
- Reported
Medicare Part D participation
Filed 1,441 Medicare Part D prescription claims in the 2023 CMS public use file — indicates active Medicare prescribing participation.
Source: CMS Part D Prescriber PUF
- Reported
CMS quality reporting (MIPS)
Reported a CMS MIPS final score of 73.6/100 in the Quality Payment Program — a federal quality measure, not a patient review.
Source: CMS Quality Payment Program
- Reported
Board certification signal
Heuristic suggests board-certified status based on ABMS-eligible specialty taxonomy plus active CMS participation signals — not a direct ABMS verification.
- Reported
Hospital affiliations
1 CMS Care Compare hospital affiliation on record — practice footprint from the Doctors and Clinicians file.
Source: CMS Care Compare
- Not in federal data
Individual sanction lookup
PlainDoctor does not publish per-provider disciplinary determinations. Confirm current license and any individual actions through the state medical board or FSMB verification service.
Source: State medical board / FSMB
This trust snapshot summarizes only what appears in federal CMS/NPPES public records. It is not a composite score, star rating, patient review, or clinical recommendation. PlainDoctor never fabricates reviews or AggregateRating schema.
CMS NPPES provider registry desk
NPI 1396726113 · Medical Oncology Physician
NPI-10 · ENUM-LEGACY · TAX-NARROW · MIPS-BELOW · RX-MID · BOOK-THIN · PHOTO-FINISH
- NPI-10 1396726113
- ENUM-LEGACY 2005
- TAX-NARROW 4,028
- MIPS-BELOW 73.6/100
- RX-MID 1,441
- BOOK-THIN 63 in Connecticut
- PHOTO-FINISH Sarah Conlon, MD · ±0.0
MIPS final-score neighbourhood
Same-specialty nationwide peers by CMS final score, not geographic proximity
- Hurwitz · this p…
Hurwitz · this provider
73.6 MIPS pts
- Sarah Conlon, MD…
Sarah Conlon, MD
73.6 MIPS pts
- Roy Herbst, M.D.…
Roy Herbst, M.D., PHD
73.6 MIPS pts
- Manoj Pillai, MD…
Manoj Pillai, MD
73.6 MIPS pts
- Mario Sznol, MD …
Mario Sznol, MD
73.6 MIPS pts
What this shows Nearest measured MIPS peers for this NUCC specialty (2023 performance year).
Michael Hurwitz, MD PHD's MIPS score vs every measured U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure. Clinicians whose score CMS assigned without scoring any category are excluded.
74 ≥ 11th percentile 11% of 454,083 measured providers are in lower value bands
Each bar is a band; taller bars hold more measured providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
The percentile is a conservative whole-score-point band: it counts only measured clinicians in lower score bands. A CMS MIPS metric is not a recommendation or a clinical-quality rating by PlainDoctor. See methodology § corpus placement.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Michael Hurwitz, MD PHD sits
This provider among medical oncology physician peers
Across the 1,398 medical oncology physician providers who report both Medicare Part D prescribing and a MIPS quality score, Michael Hurwitz, MD PHD writes more Part D claims than 87% of them and scores higher on MIPS quality than 3% - placing this provider in the high-volume, lower-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Each dot is one medical oncology physician peer from a representative sample of 60; the gold marker is Michael Hurwitz, MD PHD. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
✓
Board certification likely (heuristic, not verified)
Michael Hurwitz, MD PHD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Michael Hurwitz, MD PHD?
Below national averagePrimary specialty
Medical Oncology Physician
Medicare Part D claims
1,441 97% vs specialty avg
MIPS final score
73.6/100 9.9 pts vs avg
Specialty distribution in Connecticut
How Medical Oncology Physician compares to other specialties among Connecticut providers
Medicare quality performance, MIPS
Michael Hurwitz, MD PHD's 2023 MIPS final score plotted against the Medical Oncology Physician national average
- MIPS Final Score
- 73.6/100
- vs 83.5 national avg · 2023 performance year
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Practice Address
Provider Details
| NPI | 1396726113 |
|---|---|
| Specialty | Medical Oncology Physician |
| Credentials | MD PHD |
| Gender | Male |
| NPI Issued | 11/09/2005 |
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
73.5637
Final Score
Measured-score avg: 83.5
75.8435
Quality
51.4318
Cost
74
Promoting Interoperability
Reporting: Group practice
Hospital and facility affiliations
Facilities where Michael Hurwitz, MD PHD bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" - a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Yale University
New Haven, CT
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Brand vs generic prescribing mix · Above average
Michael Hurwitz, MD PHD - brand share 30.0%
Medical Oncology Physician average
30% brand-name claims vs 70% generic, on 1,441 2024 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2024.
1,441
Total Claims
$6.4M
Total Drug Cost
163
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 1,682.733
- Total Day Supply
- 48,358
- Brand vs Generic
- 30% brand / 70% generic
- Brand Drug Cost
- $5.6M
- Generic Drug Cost
- $791K
- Opioid Claims
- 45 (3.1% rate)
Patient Demographics
- Average Patient Age
- 75.2 years
- Avg HCC Risk Score
- 2.98
- Gender Split
- 8% female / 92% male
- Age Distribution
- <65: 11, 65-74: 71, 75-84: 54, 85+: 27
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2024. Based on Medicare Part D data only.
What Michael Hurwitz, MD PHD prescribes most
Top Medicare Part D drugs by claim count, 2024
- Prednisone
Prednisone
284 claims
- Abiraterone Acetate
Abiraterone Acetate
260 claims
- Nubeqa
Nubeqa
150 claims
- Xtandi 79
Xtandi
79 claims
- Orgovyx 62
Orgovyx
62 claims
- Venlafaxine Hcl Er 49
Venlafaxine Hcl Er
49 claims
- Welireg 46
Welireg
46 claims
- Ondansetron Odt 33
Ondansetron Odt
33 claims
| Drug | Claims |
|---|---|
| Prednisone | 284 |
| Abiraterone Acetate | 260 |
| Nubeqa Darolutamide | 150 |
| Xtandi Enzalutamide | 79 |
| Orgovyx Relugolix | 62 |
| Venlafaxine Hcl Er Venlafaxine Hcl | 49 |
| Welireg Belzutifan | 46 |
| Ondansetron Odt Ondansetron | 33 |
| Bicalutamide | 30 |
| Levothyroxine Sodium | 30 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Medical Oncology Physician Overview
How Michael Hurwitz, MD PHD fits within the Medical Oncology Physician landscape nationally.
4,028
Medical Oncology Physician Providers in US
53
States with Medical Oncology Physician
732
Avg Claims per Provider
Michael Hurwitz, MD PHD's 1,441 claims are above the specialty average of 732.
Nationwide Medical Oncology Physician peers with similar MIPS or enrollment year
Two federal-record peer sets for Hurwitz, both outside Connecticut so the neighborhoods are not geographic containment.
Similar MIPS final score
Nearest same-specialty clinicians by CMS MIPS final score (73.6 here).
Same NPPES enumeration year (2005)
Same-specialty clinicians who entered the NPI registry in the same calendar year, outside this state.
Nearby Medical Oncology Physician Providers in Connecticut
Other clinicians with the same primary specialty enrolled in Connecticut, drawn from the same CMS NPPES roster as Hurwitz.
One of 63 Medical Oncology Physician providers enrolled in Connecticut, 5 are shown here.
Dr. Ana Acuna-Villaorduna
MD
Farmington, CT
Dr. Omar Al Asad
MD
New Haven, CT
Myra Barginear
Westport, CT
Dr. Joshua Bilenker
M.D.
Stamford, CT
Dr. Kathleen Bober-Sorcinelli
MD
Meriden, CT
Compare Medical Oncology Physician nationally: see state-by-state distribution →
Frequently Asked Questions
What is Michael Hurwitz, MD PHD's specialty? ▼
Michael Hurwitz, MD PHD specializes in Medical Oncology Physician and practices in New Haven, Connecticut. Credentials: MD PHD.
How much does Michael Hurwitz, MD PHD prescribe under Medicare Part D? ▼
In 2024, Michael Hurwitz, MD PHD wrote 1,441 Medicare Part D claims totaling $6.4M in drug costs for 163 beneficiaries.
What is Michael Hurwitz, MD PHD's Medicare quality score? ▼
Michael Hurwitz, MD PHD has a CMS MIPS Final Score of 73.6/100 (Quality: 75.8, Cost: 51.4). The average MIPS Final Score across the 454,083 clinicians with at least one published category score is 83.5; clinicians whose score CMS assigned without scoring any category are excluded from that average. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is Michael Hurwitz, MD PHD located? ▼
Michael Hurwitz, MD PHD is located at 333 CEDAR ST, New Haven, CT, 06510. Phone: (203) 200-4822.
What is Michael Hurwitz, MD PHD's NPI number? ▼
Michael Hurwitz, MD PHD's National Provider Identifier (NPI) is 1396726113, issued on 11/09/2005.
Does Michael Hurwitz, MD PHD prescribe more brand-name or generic drugs? ▼
Michael Hurwitz, MD PHD's prescribing is 30% brand-name and 70% generic drugs by claim count, with $5.6M in brand drug costs.
Does Michael Hurwitz, MD PHD prescribe opioids? ▼
Yes, Michael Hurwitz, MD PHD had 45 opioid claims in 2024 with an opioid prescribing rate of 3.1%.
How many Medical Oncology Physician providers are there in the US? ▼
There are 4,028 Medical Oncology Physician providers across 53 states in the US. The average Medical Oncology Physician provider writes 732 Medicare Part D claims per year.
What drugs does Michael Hurwitz, MD PHD prescribe most often? ▼
Based on 2024 Medicare Part D data, Michael Hurwitz, MD PHD's most frequently prescribed drugs include Prednisone, Abiraterone Acetate, Nubeqa. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Michael Hurwitz, MD PHD accept Medicare? ▼
Michael Hurwitz, MD PHD appears in CMS Medicare data with 1,441 Part D claims and 163 Medicare beneficiaries in 2024. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Michael Hurwitz, MD PHD's credentials? ▼
Michael Hurwitz, MD PHD's NPI is 1396726113 with credentials MD PHD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2024). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of August 2026 (NPPES) / 2024 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.